HAEMFIX: Impact of Switching From SHL‐FIX to EHL‐FIX in Patients With Haemophilia B
Switching from SHL-FIX to EHL-FIX in children with haemophilia B is safe and may improve outcomes by reducing bleeding rates, infusion frequency, and factor consumption while enhancing joint health and HRQoL.
Authors
- Victoria Lieftüchter
- Martin Olivieri (ORCID: https://orcid.org/0000-0001-6434-6244)
- Sylvia von Mackensen (ORCID: https://orcid.org/0000-0002-5926-0478)
- Sabrina Juranek
- Christoph Bidlingmaier (ORCID: https://orcid.org/0000-0003-3755-0930)
- Susan Halimeh
- Johannes Holzapfel
- Lisa Kleinlein
- Julia Hölz
- Jasmin Lonardi
- Juliet Fleischer
- Henri Funk
Institutions
- Statistisches Bundesamt (DE)
- Universität Hamburg (DE)
- Munich School of Philosophy (DE)
- Haemophilia Foundation Australia (AU)
- University Medical Center Hamburg-Eppendorf (DE)
- Thrombosis Research Institute (GB)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Haemophilia
- Published
- 2025-10-25
- DOI
- https://doi.org/10.1111/hae.70157
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- CSL Behring
- Bayer HealthCare
- Novo Nordisk
- Swedish Orphan Biovitrum
- Chugai Pharmaceutical
- Novo Nordisk Pharma